Evidence map›Paper›PMID 36531912›Full record

ArticleJournal of cancer immunology2022

Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy.

Alberto Nobili, Aya Kobayashi, Patrick C Gedeon, Carl D Novina

Abstract read
In one paragraph

Article in Journal of cancer immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alberto NobiliDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Aya KobayashiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Patrick C GedeonDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Carl D NovinaDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Funding

Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Engineering epigenetic therapy for sickle cell diseaseDP1DK105602 · NIDDK · DANA-FARBER CANCER INST · PI NOVINA, CARL D · 2014 to 2018
$4.3M
Lnc'ing White Fat to Brown Fat ThermogenesisDP1DK126161 · NIDDK · DANA-FARBER CANCER INST · PI NOVINA, CARL D · 2020 to 2020
$885k
NIDDK NIH HHS DP1 DK105602NIDDK NIH HHS DP1 DK126161NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36531912
PMCPMC9754302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.